Pharmacokinetics of erythromycin estolate and erythromycin phosphate after intragastric administration to healthy foals

Jeffrey Lakritz, William D Wilson, Antoinette E. Marsh, Judy E. Mihalyi

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Objective - To determine pharmacokinetics and plasma concentrations of erythromycin and related compounds after intragastric administration of erythromycin phosphate and erythromycin estolate to healthy foals. Animals - 11 healthy 2- to 6-month-old foals. Procedure - Food was withheld from foals overnight before intragastric administration of erythromycin estolate (25 mg/kg of body weight; n = 8) and erythromycin phosphate (25 mg/kg; 7). Four foals received both drugs with 2 weeks between treatments. Plasma erythromycin concentrations were determined at various times after drug administration by use of high-performance liquid chromatography. Maximum plasma peak concentrations, time to maximum concentrations, area under plasma concentration versus time curves, half-life of elimination, and mean residence times were determined from concentration versus time curves. Results - Maximum peak concentration of erythromycin A after administration of erythromycin phosphate was significantly greater than after administration of erythromycin estolate (2.9 ± 1.1 μg/ml vs 1.0 ± 0.82 μg/ml). Time to maximum concentration was shorter after administration of erythromycin phosphate than after erythromycin estolate (0.71 ± 0.29 hours vs 1.7 ± 1.2 hours). Concentrations of anhydroerythromycin A were significantly less 1 and 3 hours after administration of erythromycin estolate than after administration of erythromycin phosphate. Conclusions and Clinical Relevance - Plasma concentrations of erythromycin A remained > 0.25 μg/ml (reported minimum inhibitory concentration for Rhodococcus equi) for at least 4 hours after intragastric administration of erythromycin phosphate or erythromycin estolate, suggesting that the recommended dosage for either formulation (25 mg/kg, q 6 h) should be adequate for treatment of Requi infections in foals.

Original languageEnglish (US)
Pages (from-to)914-919
Number of pages6
JournalAmerican Journal of Veterinary Research
Volume61
Issue number8
StatePublished - Aug 2000

Fingerprint

Erythromycin Estolate
intragastric administration
erythromycin
Erythromycin
foals
pharmacokinetics
Pharmacokinetics
phosphates
Rhodococcus equi
Microbial Sensitivity Tests
Pharmaceutical Preparations
Half-Life

ASJC Scopus subject areas

  • veterinary(all)

Cite this

Pharmacokinetics of erythromycin estolate and erythromycin phosphate after intragastric administration to healthy foals. / Lakritz, Jeffrey; Wilson, William D; Marsh, Antoinette E.; Mihalyi, Judy E.

In: American Journal of Veterinary Research, Vol. 61, No. 8, 08.2000, p. 914-919.

Research output: Contribution to journalArticle

@article{66da02142e244b6dbb7f02bf881d6962,
title = "Pharmacokinetics of erythromycin estolate and erythromycin phosphate after intragastric administration to healthy foals",
abstract = "Objective - To determine pharmacokinetics and plasma concentrations of erythromycin and related compounds after intragastric administration of erythromycin phosphate and erythromycin estolate to healthy foals. Animals - 11 healthy 2- to 6-month-old foals. Procedure - Food was withheld from foals overnight before intragastric administration of erythromycin estolate (25 mg/kg of body weight; n = 8) and erythromycin phosphate (25 mg/kg; 7). Four foals received both drugs with 2 weeks between treatments. Plasma erythromycin concentrations were determined at various times after drug administration by use of high-performance liquid chromatography. Maximum plasma peak concentrations, time to maximum concentrations, area under plasma concentration versus time curves, half-life of elimination, and mean residence times were determined from concentration versus time curves. Results - Maximum peak concentration of erythromycin A after administration of erythromycin phosphate was significantly greater than after administration of erythromycin estolate (2.9 ± 1.1 μg/ml vs 1.0 ± 0.82 μg/ml). Time to maximum concentration was shorter after administration of erythromycin phosphate than after erythromycin estolate (0.71 ± 0.29 hours vs 1.7 ± 1.2 hours). Concentrations of anhydroerythromycin A were significantly less 1 and 3 hours after administration of erythromycin estolate than after administration of erythromycin phosphate. Conclusions and Clinical Relevance - Plasma concentrations of erythromycin A remained > 0.25 μg/ml (reported minimum inhibitory concentration for Rhodococcus equi) for at least 4 hours after intragastric administration of erythromycin phosphate or erythromycin estolate, suggesting that the recommended dosage for either formulation (25 mg/kg, q 6 h) should be adequate for treatment of Requi infections in foals.",
author = "Jeffrey Lakritz and Wilson, {William D} and Marsh, {Antoinette E.} and Mihalyi, {Judy E.}",
year = "2000",
month = "8",
language = "English (US)",
volume = "61",
pages = "914--919",
journal = "American Journal of Veterinary Research",
issn = "0002-9645",
publisher = "American Veterinary Medical Association",
number = "8",

}

TY - JOUR

T1 - Pharmacokinetics of erythromycin estolate and erythromycin phosphate after intragastric administration to healthy foals

AU - Lakritz, Jeffrey

AU - Wilson, William D

AU - Marsh, Antoinette E.

AU - Mihalyi, Judy E.

PY - 2000/8

Y1 - 2000/8

N2 - Objective - To determine pharmacokinetics and plasma concentrations of erythromycin and related compounds after intragastric administration of erythromycin phosphate and erythromycin estolate to healthy foals. Animals - 11 healthy 2- to 6-month-old foals. Procedure - Food was withheld from foals overnight before intragastric administration of erythromycin estolate (25 mg/kg of body weight; n = 8) and erythromycin phosphate (25 mg/kg; 7). Four foals received both drugs with 2 weeks between treatments. Plasma erythromycin concentrations were determined at various times after drug administration by use of high-performance liquid chromatography. Maximum plasma peak concentrations, time to maximum concentrations, area under plasma concentration versus time curves, half-life of elimination, and mean residence times were determined from concentration versus time curves. Results - Maximum peak concentration of erythromycin A after administration of erythromycin phosphate was significantly greater than after administration of erythromycin estolate (2.9 ± 1.1 μg/ml vs 1.0 ± 0.82 μg/ml). Time to maximum concentration was shorter after administration of erythromycin phosphate than after erythromycin estolate (0.71 ± 0.29 hours vs 1.7 ± 1.2 hours). Concentrations of anhydroerythromycin A were significantly less 1 and 3 hours after administration of erythromycin estolate than after administration of erythromycin phosphate. Conclusions and Clinical Relevance - Plasma concentrations of erythromycin A remained > 0.25 μg/ml (reported minimum inhibitory concentration for Rhodococcus equi) for at least 4 hours after intragastric administration of erythromycin phosphate or erythromycin estolate, suggesting that the recommended dosage for either formulation (25 mg/kg, q 6 h) should be adequate for treatment of Requi infections in foals.

AB - Objective - To determine pharmacokinetics and plasma concentrations of erythromycin and related compounds after intragastric administration of erythromycin phosphate and erythromycin estolate to healthy foals. Animals - 11 healthy 2- to 6-month-old foals. Procedure - Food was withheld from foals overnight before intragastric administration of erythromycin estolate (25 mg/kg of body weight; n = 8) and erythromycin phosphate (25 mg/kg; 7). Four foals received both drugs with 2 weeks between treatments. Plasma erythromycin concentrations were determined at various times after drug administration by use of high-performance liquid chromatography. Maximum plasma peak concentrations, time to maximum concentrations, area under plasma concentration versus time curves, half-life of elimination, and mean residence times were determined from concentration versus time curves. Results - Maximum peak concentration of erythromycin A after administration of erythromycin phosphate was significantly greater than after administration of erythromycin estolate (2.9 ± 1.1 μg/ml vs 1.0 ± 0.82 μg/ml). Time to maximum concentration was shorter after administration of erythromycin phosphate than after erythromycin estolate (0.71 ± 0.29 hours vs 1.7 ± 1.2 hours). Concentrations of anhydroerythromycin A were significantly less 1 and 3 hours after administration of erythromycin estolate than after administration of erythromycin phosphate. Conclusions and Clinical Relevance - Plasma concentrations of erythromycin A remained > 0.25 μg/ml (reported minimum inhibitory concentration for Rhodococcus equi) for at least 4 hours after intragastric administration of erythromycin phosphate or erythromycin estolate, suggesting that the recommended dosage for either formulation (25 mg/kg, q 6 h) should be adequate for treatment of Requi infections in foals.

UR - http://www.scopus.com/inward/record.url?scp=0033901249&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033901249&partnerID=8YFLogxK

M3 - Article

VL - 61

SP - 914

EP - 919

JO - American Journal of Veterinary Research

JF - American Journal of Veterinary Research

SN - 0002-9645

IS - 8

ER -